Jubilant Pharmova Quarterly Results
Jubilant Pharmova quarterly results. In Sept 2026, Jubilant Pharmova (JUBLPHARMA) reported revenue ₹2,375 Cr and net profit ₹31 Cr — revenue +20.7% YoY. Also explore JUBLPHARMA price trends to track price trends across different timeframes.
JUBLPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Jubilant Pharmova latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View JUBLPHARMA 52-week high low for the annual high/low range and current price position.
- Revenue of ₹2,375 Cr in Sept 2026 (+3.4% vs Mar 2026, +20.7% vs Sept 2025)
- Net Profit of ₹31 Cr in Sept 2026 (-73.9% vs Mar 2026, -74.2% vs Sept 2025)
- EBITDA of ₹245 Cr in Sept 2026 (-26.2% vs Mar 2026)
- Operating Margin of 10.0% in Sept 2026 (-4.0pp vs Mar 2026)
- Earnings Per Share of ₹1.97 in Sept 2026 (-73.9% vs Mar 2026)
Jubilant Pharmova Quarterly Results — Revenue, EBITDA, Net Profit & EPS
JUBLPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,375 | 2,296 | 2,241 | 1,968 | 1,928 | 3.4% | 20.7% |
| Net Profit (₹ Cr) | 31 | 119 | 56 | 120 | 151 | - | - |
| EBITDA (₹ Cr) | 245 | 332 | 260 | 337 | 341 | - | - |
| EPS (₹) | 1.97 | 7.55 | 3.57 | 7.59 | 9.71 | - | - |
| Operating Margin (%) | 10.0% | 14.0% | 11.0% | 17.0% | 17.0% | - | - |
JUBLPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Jubilant Pharmova 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Jubilant Pharmova share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
JUBLPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Jubilant Pharmova latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores